Figure 4 summarizes the results of the LOH-analyses for both carriers and non-carriers, and combines these with some clinical (tumor type, age of onset) and pathological (ER/PgR/HER2-immunostaining) information. This evidence concerns the gene ESR1 and neoplasm.